neurological conditions

Ageing, long-term complications and nutrition

Graham Stocks — Wed, 01 Sep 2010 18:50:30 -0700

Reporting back from the AIDS Conference in Vienna, DAVID MENADUE discovers that ‘HIV and ageing’ is a universal issue, that long-term complications may be more prevalent than we thought and that good nutrition really is a good idea.

Mental Health

Graham Stocks — Wed, 07 Apr 2010 23:43:24 -0700

HIV brings changes to our lives and it challenges us, but it’s a virusA small infective organism which is incapable of reproducing outside a host cell.; it is not who we are. There are many things you can do to help manage these challenges. Talking to a counsellor can help or there are organisations that offer courses to help you develop coping skills, including on-line courses.

Mind your head

Graham Stocks — Wed, 25 Nov 2009 19:17:07 -0800

You are usually the first one to notice if something is going wrong with your health. If you’re lucky, the symptoms are simple to explain and to treat. If they’re a little more mercurial in nature and involve your neurocognitive functions, then you and your doctor need to work a little bit harder to sort things out . . .

HAART dramatically improves survival in relation to neurological AIDS diseases

Sat, 01 Dec 2007 00:00:00 -0800

Survival after diagnosis with AIDS-related neurological illnesses has improved since the advent of HAARTHighly Active AntiRetroviral Therapy ??? aggressive treatment of HIV infection using several different drugs together., according to an abstract presented to the eleventh European AIDS Conference (EACS). Furthermore, patients on ARVA medication or other substance which is active against retroviruses such as HIV. regimens containing a higher number of drugs that crossed the ‘blood-brain barrier’ and got into the central nervous system (CNS) had better survival rates.

The pointy end of crystal

Wed, 18 Jan 2006 06:06:42 -0800

With an emerging body of evidence showing that regular crystal meth use can cause changes to the structure and functioning of the brain, positive people have good reasons to be cautious about this drug. KIRSTY MACHON reports.

Looking into the eye of the tiger

David Menadue — Wed, 18 May 2005 07:00:51 -0700

My concern started when an email with the monthly ‘HIV Newsclips’ arrived on my desktop. “People with diabetes[Diabetes mellitus] A disorder in which sugars in the diet cannot be metabolised into energy due to a lack of the enzyme insulin. Late-onset diabetes mellitus may be a long-term side effect of some anti-HIV drugs. at greater risk of HIV-associated dementia,” it said, and proceeded to outline research at the University of Hawaii where a higher percentage of positive people who had developed diabetes after taking HAARTHighly Active AntiRetroviral Therapy ??? aggressive treatment of HIV infection using several different drugs together. were showing signs of cognitive impairment.

Brain bank hopes to beat dementia

Paul Kidd — Thu, 14 Oct 2004 13:00:44 -0700

It’s one of the scariest prospects facing HIV-positive people. The possibility of developing AIDS-related dementia or other brain and central nervous system diseases fills many of us with justifiable fear. Like mental illness, brain disease strikes at the very core of who we are.

Neurological and psychological complications of HIV

Brent Beadle — Fri, 31 Oct 2003 06:00:26 -0800

This Treataware fact sheet looks at the various neurological and psychological illnesses that affect people with HIV/AIDS including AIDS dementia complex, toxoplasmosis, PML, lymphoma and depression.

Dementia persists despite HAART

Paul Kidd — Thu, 31 Jul 2003 07:00:27 -0700

An Australian study has found that while people diagnosed with AIDS dementia complex (ADC) are surviving significantly longer due to improved antiretroviralA medication or other substance which is active against retroviruses such as HIV. efficacy(Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the standard procedure, Phase II clinical trials gauge efficacy, and Phase III trials confirm it., the prevalence of ADC has risen since the advent of highly active antiretroviral therapy (HAARTHighly Active AntiRetroviral Therapy ??? aggressive treatment of HIV infection using several different drugs together.).